RxDoctor Payments Data

Bhaskara Gadi, MD

Hematology & Oncology · Festus, MONPI 1821057365

Payments from drug & device makers

$143in general payments, 2019–2025

Across 8 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tempus AI, Inc$37
  • Gilead$29
  • Fresenius Kabi USA, LLC$27
  • Astellas Pharma US Inc$22
  • Regeneron Healthcare Solutions, Inc.$17
  • Exelixis Inc.$12

What the payments were for

  • Food & beverage$10372%
  • Education$4128%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$143 in reported general payments places this provider in the 10th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$117,044
Medicare patients
436
Services billed
1,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide58$1,035,876
PromactaEltrombopag Olamine28$414,121
CabometyxCabozantinib S-Malate12$311,133
IbrancePalbociclib20$291,740
LumakrasSotorasib12$238,189
TagrissoOsimertinib Mesylate12$203,874
ImbruvicaIbrutinib13$203,524
TasignaNilotinib Hcl14$197,294
JakafiRuxolitinib Phosphate11$193,068
EliquisApixaban182$130,441
NinlaroIxazomib Citrate11$126,610
XareltoRivaroxaban17$13,298
Imatinib Mesylate24$8,957
Anastrozole152$2,704
ValacyclovirValacyclovir Hcl53$2,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$12$311,13312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Festus

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →